STOCK TITAN

SINTX Technologies Inc - SINT STOCK NEWS

Welcome to our dedicated news page for SINTX Technologies (Ticker: SINT), a resource for investors and traders seeking the latest updates and insights on SINTX Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SINTX Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SINTX Technologies's position in the market.

Rhea-AI Summary
SINTX Technologies, Inc. (SINT) announced the pricing of a public offering of 28.4 million shares of common stock at $0.047 per share, aiming to raise $1.3 million for working capital and corporate purposes. The offering is expected to close on March 26, 2024, with Maxim Group as the placement agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-45.95%
Tags
offering
-
Rhea-AI Summary
SINTX Technologies, Inc. announces a public offering of its common stock to raise funds for working capital and general corporate purposes. The offering, managed by Maxim Group , is subject to market conditions and aims to utilize the net proceeds for operational needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.99%
Tags
offering
-
Rhea-AI Summary
SINTX Technologies, Inc. announces a 10-year Long-Term Agreement with a leading aerospace manufacturer, valued at up to $8 million. The agreement focuses on manufacturing ceramic aircraft engine components, expanding SINTX's reach beyond the biomedical sector. SINTX's Quality Management System is certified for aerospace and biomedical sectors, showcasing their expertise and capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
none
Rhea-AI Summary
SINTX Technologies, Inc. (SINT) has closed a public offering of 16,000,000 units, each consisting of one share of common stock and various warrants, at a public offering price of $0.25 per unit. The gross proceeds are approximately $4.0 million. The offering was made pursuant to a registration statement on Form S-1, declared effective by the SEC on January 31, 2024. Maxim Group LLC acted as sole placement agent, and Ascendiant Capital Markets LLC acted as the Company’s financial advisor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
offering
-
Rhea-AI Summary
SINTX Technologies, Inc. (SINT) announced a public offering of 16,000,000 units, each consisting of one share of common stock, a pre-funded warrant, and two types of warrants, with gross proceeds expected to be approximately $4.0 million. The offering is expected to close on February 2, 2024, and is being made pursuant to a registration statement declared effective by the SEC on January 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.47%
Tags
offering
-
Rhea-AI Summary
SINTX Technologies, Inc. (NASDAQ: SINT) announced a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Combat Capabilities Development Command Army Research Laboratory (DEVCOM ARL) to collaborate on ceramic additive manufacturing and ceramic matrix composites. This partnership is expected to leverage the strengths of both organizations in developing advanced technologies for hypersonic vehicle applications and other high-temperature materials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.47%
Tags
none
Rhea-AI Summary
SINTX Technologies, Inc. reported estimated unaudited revenues of approximately $902k in Q4 2023 and $2.6 million for the year ended December 31, 2023. This represents an 18% increase in Q4 2023 revenue versus Q4 2022, and a 68% increase in 2023 revenue compared to 2022. The 2023 revenue figures reflect a 333% increase in revenues for the year that ended December 31, 2021. Commercial revenues of $582K in Q4 2023 and $1.2 million for the full year 2023 were achieved primarily by the sale of products in the aerospace, biomedical, and energy markets. Government contracts in these markets made up $320K in Q4 and $1.4 million for the full year. SINTX anticipates continued revenue growth in 2024 driven primarily by new commercial product adoption, innovative technology development, and government contract opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
earnings
-
Rhea-AI Summary
SINTX Technologies, Inc. (SINT) has been granted its sixth United States patent in the last year, all related to the antipathogenic properties of silicon nitride. The significance of the patents lies in their innovative approaches towards utilizing silicon nitride in a wide range of antipathogenic solutions, covering applications in agriculture, dentistry, medical implants, durable medical equipment, and personal protective equipment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
Rhea-AI Summary
SINTX Technologies, Inc. has entered a Long-Term Agreement to supply jet engine components made of its silicon nitride, expanding its capabilities beyond biomedical implants. The agreement has no minimum requirements and is projected to generate annual revenues of less than $0.25 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.5%
Tags
none
Rhea-AI Summary
SINTX Technologies has been awarded a Phase II grant of $1,972,826 by the NIH to develop a 3D printed composite spinal implant. The grant represents a critical milestone in expanding the antibacterial and osseointegrative properties of silicon nitride into composite structures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
clinical trial
SINTX Technologies Inc

Nasdaq:SINT

SINT Rankings

SINT Stock Data

440.39k
4.26M
0.09%
18.1%
1.74%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Salt Lake City

About SINT

amedica is the only manufacturer of medical grade silicon nitride, an innovative biomaterial technology ideal for use in spinal fusion and across a variety of medical applications. our silicon nitride features a unique nanosurface texture that promotes bone growth and addresses clinical needs by providing excellent imaging capabilities and demonstrating antibacterial characteristics. our interbody fusion devices and pedicle screw systems are designed to benefit both the patient and the surgeon. with the only fda registered and iso 1345 certified silicon nitride medical device manufacturing facility in the world and a strong sales and distribution organization, we are committed to providing innovative healthcare solutions that improve patient quality of life.